Prime Medicine (PRME) Plunge 14.59% to 2025 Low on Wider-Than-Expected Q3 Losses, Revenue Miss

The share price fell to its lowest level since September 2025 today, with an intraday decline of 14.59%.

Prime Medicine (PRME) reported a wider-than-expected net loss of $0.32 per share in Q3 2025, missing the Zacks Consensus Estimate of $0.28 per share. Revenue dropped to $1.23 million, a 75.35% shortfall from the Zacks estimate and a sharp decline from $0.21 million in the prior-year period. Over the past four quarters, the company has only surpassed earnings estimates once and has consistently underperformed revenue forecasts. These recurring financial shortfalls highlight operational inefficiencies and raise concerns about scalability, contributing to recent volatility.

Key pipeline updates include plans to file IND/CTA applications for Wilson’s Disease and Alpha-1 Antitrypsin Deficiency programs in 2026, with clinical data expected in 2027. Preclinical results for PM577 will be presented at the AASLD conference on November 9, a pivotal moment for investor sentiment. Despite a $227 million cash runway through 2027, Q3 net losses widened to $50.6 million, driven by $44 million in R&D expenses. Leadership changes, including the appointment of a new Chief Business Officer, and an upcoming KOL event on November 12 aim to bolster strategic clarity. Analysts remain cautiously optimistic, with a median price target of $7.00, though regulatory and clinical uncertainties—alongside competitive pressures—pose near-term risks.